Hims & Hers Health, Inc. $HIMS Holdings Decreased by Wellington Management Group LLP

Wellington Management Group LLP trimmed its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 67.8% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 313,463 shares of the company’s stock after selling 660,843 shares during the period. Wellington Management Group LLP’s holdings in Hims & Hers Health were worth $10,868,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Kelly Lawrence W & Associates Inc. CA purchased a new position in Hims & Hers Health during the 2nd quarter valued at about $11,520,000. Bank of New York Mellon Corp purchased a new stake in shares of Hims & Hers Health in the second quarter worth approximately $46,220,000. Handelsbanken Fonder AB lifted its position in shares of Hims & Hers Health by 4.0% in the second quarter. Handelsbanken Fonder AB now owns 60,000 shares of the company’s stock worth $2,080,000 after purchasing an additional 2,300 shares in the last quarter. Valeo Financial Advisors LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth approximately $225,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth approximately $347,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Trading Down 0.2%

Shares of NYSE:HIMS opened at $27.66 on Tuesday. The stock has a market capitalization of $6.45 billion, a PE ratio of -43.90 and a beta of 2.42. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $65.30. The firm has a fifty day moving average price of $31.55 and a 200 day moving average price of $26.90. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same period in the previous year, the company earned $0.17 earnings per share. The company’s quarterly revenue was up 38.2% compared to the same quarter last year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 25,111 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05. Following the transaction, the insider owned 313,964 shares in the company, valued at $8,649,708.20. This trade represents a 7.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Patrick Carroll sold 23,726 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the completion of the transaction, the insider directly owned 181,861 shares in the company, valued at approximately $6,365,135. This represents a 11.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 190,227 shares of company stock worth $6,133,613 in the last three months. 11.76% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. TD Cowen boosted their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Barclays dropped their price target on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research note on Friday, August 21st. Citigroup reduced their price target on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. lowered their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $32.50.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.